Skip to main content

Table 3 Distribution of patients who discontinued treatment - by LOT and time of discontinuation

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

LOT Received treatment, n Still on treatment at EOFU, n (%) Discontinued treatment
Time to discontinuation, months
Mean (SD)
Within 6 months of LOT initiation After 6 months of LOT initiation
All patients (n = 213)
 LOT1 213 51 (23.9%) 29.4 (31.8) 36 (16.9%) 126 (59.2%)
 LOT2 150 42 (28.0%) 20.2 (20.4) 29 (19.3%) 79 (52.7%)
 LOT3 101 43 (42.6%) 16.7 (16.2) 20 (19.8%) 38 (37.6%)
 LOT4 48 18 (37.5%) 22.2 (25.1) 11 (22.9%) 19 (39.6%)
Received abatacept
 LOT1 68 51 (75.0%) 13.0 (12.4) 5 (7.4%) 12 (17.6%)
 LOT2 59 40 (67.8%) 12.7 (10.7) 7 (11.9%) 12 (20.3%)
 LOT3 50 38 (76.0%) 12.1 (6.9) 4 (8.0%) 8 (16.0%)
 LOT4 23 11 (47.8%) 10.7 (11.0) 5 (21.7%) 7 (30.4%)
Received other bDMARD
 LOT1 145 0 (0.0%) 31.4 (32.8) 31 (21.4%) 114 (78.6%)
 LOT2 91 2 (2.2%) 21.8 (21.6) 22 (24.2%) 67 (73.6%)
 LOT3 51 5 (9.8%) 17.9 (17.7) 16 (31.4%) 30 (58.8%)
 LOT4 25 7 (28.0%) 29.9 (29.0) 6 (24.0%) 12 (48.0%)
  1. bDMARD Biologic disease-modifying antirheumatic drugs, EOFU End of follow-up, LOT Line of therapy. lOTs 5–8 removed due to a high proportion requiring small number suppression